Interleukin-21 has activity in patients with metastatic melanoma: A phase II study

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages 3396-3401

  Petrella, Teresa M ^a   Tozer, Richard ^c   Belanger, Karl ^f   Savage, Kerry J ^g   Wong, Ralph ^h   Smylie, Michael ⁱ   Kamel Reid, Suzanne ^b   Tron, Victor ^d   Chen, Bingshu E ^e   Hunder, Naomi N ^j   Hagerman, Linda ^e   Walsh, Wendy ^e   Eisenhauer, Elizabeth A ^e  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e Queen's Cancer Research Institute   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h ST BONIFACE GENERAL HOSPITAL   (Canada)

ⁱ CROSS CANCER INSTITUTE   (Canada)

^j ZYMOGENETICS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPOTENSION; IMMUNOGENICITY; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MUTATION; MYALGIA; NAUSEA AND VOMITING; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; RIGOR; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, PHARMACOLOGICAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKINS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84866772544     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.0655     Document Type: Article

References (21)

1. Parrish-Novak J, Dillon SR, Nelson A, et al: Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57-63, 2000
2. Leonard WJ, Zeng R, Spolski R: Interleukin 21: A cytokine/cytokine receptor system that has come of age. J Leukoc Biol 84:348-356, 2008
3. di Carlo E, de Totero D, Piazza T, et al: Role of IL-21 in immune-regulation and tumor immunotherapy. Cancer Immunol Immunother 56:1323-1334, 2007
4. Frederiksen KS, Lundsgaard D, Freeman JA, et al: IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 57:1439-1449, 2008
5. Kim-Schulze S, Kim HS, Fan Q, et al: Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther 17:380-388, 2009
6. Hashmi MH, Van Veldhuizen PJ: Interleukin-21: Updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther 10:807-817, 2010
7. Davis ID, Skrumsager BK, Cebon J, et al: An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 13:3630-3636, 2007
8. Thompson JA, Curti BD, Redman BG, et al: Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 26:2034-2039, 2008
9. Schmidt H, Brown J, Mouritzen U, et al: Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: A phase I trial. Clin Cancer Res 16:5312-5319, 2010
10. Davis ID, Brady B, Kefford RF, et al: Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: A phase IIa trial. Clin Cancer Res 15:2123-2129, 2009
11. Tsuchida Y, Therasse P: Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol 37:1-3, 2001
12. Zee B, Melnychuk D, Dancey J, et al: Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Stat 9:351-363, 1999
13. Korn EL, Liu PY, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008
14. Rubin LA, Kurman CC, Fritz ME, et al: Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172-3177, 1985
15. Sabatino M, Kim-Schulze S, Panelli MC, et al: Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 27:2645-2652, 2009
16. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
17. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/ S9111/C9190. J Clin Oncol 18:2444-2458, 2000
18. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
19. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
20. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011
21. Skak K, Kragh M, Hausman D, et al: Interleukin 21: Combination strategies for cancer therapy. Nat Rev Drug Discov 7:231-240, 2008